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plant lymphoproliferative disorder. This review discusses the 
clinical and histopathological aspects of skin cancers in OTR, 
the impact of dermatopathological analysis on prognosis 
and the understanding of the pathogenesis of these neo-
plasms.  Copyright © 2013 S. Karger AG, Basel 
 Introduction 
 Organ transplantation recipients (OTR) receive im-
munosuppressive treatment to maintain adequate graft 
function. Apart from this beneficial and intended effect, 
the immunosuppression and consecutively decreased im-
munosurveillance, however, carry the risk for the devel-
opment of a wide variety of cancers including epithelial 
skin cancer, Merkel cell carcinoma (MCC) and Kaposi’s 
sarcoma (KS). The spectrum of skin cancers in OTR and 
their prevalence depends on the grafted organ, the inten-
sity and composition as well as the duration of the immu-
nosuppressive therapy, UV light exposure, genetic factors 
and immunological control of oncogenic viruses which 
are involved in the pathogenesis of skin neoplasias. Skin 
tumors represent a major part of transplantation-related 
morbidity and mortality. Among the epithelial skin
cancers, squamous cell carcinoma (SCC) and basal cell 
carcinoma (BCC) account for more than 90% of all skin 
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 Abstract 
 Organ transplant recipients (OTR) are at a significantly in-
creased risk for developing a wide variety of skin cancers, 
particularly epithelial skin cancer, Merkel cell carcinoma and 
Kaposi’s sarcoma. Melanoma, skin adnexal neoplasm and cu-
taneous lymphomas are also more common in OTR and may 
differ in their clinicopathologic presentation from tumors in 
immunocompetent patients. The accuracy of clinical diag-
nosis of suspected premalignant and malignant skin lesions 
in OTR is modest. Therefore, histopathological diagnosis is 
an essential element for the diagnostic workup of skin can-
cers and, in addition, provides important information on 
prognosis. Squamous cell carcinoma and intraepithelial neo-
plasias (actinic keratosis, squamous cell carcinoma in situ or 
Bowen’s disease) are the most common forms of skin cancer 
in OTR. The risk of Merkel cell carcinoma and Kaposi’s sar-
coma is dramatically increased in OTR. Merkel cell carcinoma 
shows a highly aggressive course. Kaposi’s sarcoma tends to 
spread to extracutaneous sites. Primary cutaneous lympho-
mas developing after organ transplantation are rare. The 
spectrum of cutaneous B cell lymphomas in OTR, in particu-
lar, differs significantly from that of the general population, 
with a predominance of Epstein-Barr virus-driven posttrans-
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cancers in OTR (for review see  [1] ). Primary cutaneous 
lymphomas appearing in OTR are rare and differ signifi-
cantly from posttransplant lymphoproliferative disorder 
(PTLD) at other extranodal sites. In an organ-specific 
manner, there is a preponderance of T cell-derived, Ep-
stein-Barr virus-negative lymphoproliferations. The less 
frequent primary cutaneous B cell-derived PTLD is usu-
ally monomorphic with a blastic morphology and an ag-
gressive biological behavior.
 As the accuracy of clinical diagnosis of suspected pre-
malignant and malignant skin lesions in OTR is limited, 
the histopathological diagnosis is essential for the diag-
nostic workup of skin cancers  [2] . In this review, we dis-
cuss the pathogenetic aspects and the clinicopathological 
features of the most common skin cancers and lympho-
mas in OTR.
 Epithelial Skin Neoplasms 
 SCC and Its Precursors 
 Cutaneous SCC is the most common skin cancer in 
OTR and occurs 65–250 times more frequently than in 
the general population  [3] . Within 20 years of transplan-
tation, 20–75% of OTR are affected by at least one SCC. 
The high incidence of SCC results in an SCC to BCC ratio 
of 5: 1 in OTR. This ratio differs from the one in the gen-
eral population, in which BCC is more prevalent than 
SCC (ratio SCC to BCC = 1: 4)  [1] . Men are at a higher risk 
for SCC  [3, 4] . UV-light-exposed body regions are the 
predilection sites for SCC, its precursors actinic/solar 
keratosis (AK) and SCC in situ.
 AK presents with erythematous and often hyperkera-
totic skin lesions. Field cancerization with multiple AK 
within one anatomic region is a common finding  [5] . 
AK is characterized by disarranged stratification of the 
lower part of the epidermis and dysplastic keratinocytes 
which may extend into the upper parts of the hair follicle 
epithelium. Acantholysis and hyperparakeratosis, often 
alternating with orthokeratosis, as well as increased mel-
anin deposition are common findings. In Bowen’s dis-
ease (BD), the epidermis shows full-thickness atypia 
with enlarged and sometimes multinucleated keratino-
cytes with prominent nuclear pleomorphism and atypi-
cal mitoses. BD often occurs multifocally in OTR and 
also arises in body areas protected from UV light such 
as the trunk or in the anogenital area. A rather dense in-
flammatory infiltrate composed of lymphocytes, histio-
cytes and plasma cells is common in AK and BD. Early 
recognition and treatment of precancerous lesions are 
recommended to prevent the development of invasive 
tumors  [6] .
 SCC manifests with a hyperkeratotic or ulcerated 
plaque or nodule ( fig. 1 ). Histologically, it shows invasive 
growth of epithelial tumor cells arising from the epider-
mis ( fig. 2 ). Ulceration is common. The neoplastic cells 
show squamous differentiation with variable degrees of 
keratinization, mitoses and prominent nuclear pleomor-
phism, particularly at the invasion front and in poorly 
differentiated SCC. Differentiation (grading) of SCC in 
OTR does not differ from SCC in the general population 
 Fig. 1. SCC: hyperkeratotic plaque on the lower lip in a renal trans-
plant recipient. 
 Fig. 2. SCC: proliferation of epithelial cells with squamous differ-
entiation. Note hyperkeratosis. HE. Original magnification ×2.5. 
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 [4] . SCC in OTR presents more often with spindle cell 
morphology found in 20% of the lesions, and acantholysis 
 [4, 7] . Expression of cytokeratins (especially CK 5/6), p63 
and CAM5.2 is particularly helpful for proving the epi-
thelial origin of spindle cell SCC. Perineural growth ap-
pears not to be more frequent in OTR, but it indicates 
more extensive growth and a higher risk of recurrence  [4, 
8, 9] . The peritumoral inflammatory infiltrate is signifi-
cantly less intense in OTR  [4] . Verrucous SCC represents 
a highly differentiated form of SCC, which more com-
monly arises in the anogenital area and oral mucosa. His-
tologically, it shows blunt-ended epithelial proliferations 
with bulbous downgrowths. As the malignant nature of 
this SCC variant may be readily overlooked in small and 
superficial biopsies, its diagnosis often requires large bi-
opsies as well as the clinicopathological correlation. Prog-
nostic markers in SCC of an increased recurrence rate 
and/or poor prognosis due to subsequent metastasis in-
clude localization (the ear, lip, scalp and temple are pri-
mary sites), tumor thickness (>4 mm), tumor size (>2 
cm), Clark level IV, poor differentiation, spindle cell mor-
phology, ulceration, acantholytic changes, single cell in-
vasion, perineural growth and bone invasion  [10, 11] . 
 The pathogenesis of SCC is multifactorial, involving 
human papillomaviruses, UV-light-induced genetic 
changes and altered tumor microenvironment. Remark-
ably, immunosuppressive drugs, such as azathioprine, and 
UV light radiation act synergistically mutagenic  [12, 13] . 
Infection with beta human papillomaviruses is associated 
with an increased risk of SCC, and susceptibility to UV 
light and SCC is stronger in beta human papillomavirus-
seropositive patients  [14] . Genetic alterations of the tumor 
suppressor gene p53 have been found in premalignant and 
malignant skin lesions of renal transplant recipients (RTR) 
 [15] . A subset of SCC harbors mutations of H-RAS, but 
not K-RAS or N-RAS, and alterations of CDKN2A  [16] . 
Loss of heterozygosity can be observed in SCC of OTR as 
well as in the general population  [17] . MicroRNA-21 and 
microRNA-184 are upregulated in SCC of OTR and their 
expression is increased by UVA light  [18] . The tumor mi-
croenvironment is characterized by a reduced number of 
CD123+ plasmacytoid dendritic cells and FOXP3+ T cells 
in the peritumoral inflammatory infiltrate; this is associ-
ated with progression of SCC in OTR  [8] .
 Surgical excision including Mohs surgery is the first-
line therapy of SCC  [6, 19] . A reduction of immunosup-
pressive drugs should be considered in patients with sev-
eral SCC or multifocal BD and those with metastatic SCC 
 [6] . Conversion from calcineurin inhibitors to the mTOR 
inhibitor sirolimus reduces the thickness and vasculariza-
tion of SCC in OTR and should be considered in early 
SCC development, in particular  [20, 21] .
 Basal Cell Carcinoma 
 BCC is the second most frequent cancer in OTR  [1, 3] 
with a 10- to 16-fold increased risk among OTR com-
pared to the general population. In a retrospective study, 
BCC was found in 14.5% of RTR and manifests with a 
delay of 5–11 years after the transplant  [22] . UV-light-
exposed body regions, particularly the head and neck, are 
predilection sites. There are numerous clinical and histo-
logical variants of BCC  [23] , but the clinical and histo-
logical features of BCC in OTR do not differ significantly 
from those in immunocompetent individuals. Nodular 
BCC is the most common form seen in OTR ( fig. 3 ). It 
presents clinically as a nodular lesion, often undergoing 
ulceration, and histologically as variably sized nodular 
proliferations of basaloid epithelial cells displaying a 
characteristic palisading arrangement of nuclei at the pe-
riphery. Cystic foci, adnexal differentiation and pigmen-
tation may be present. The tumor islands are separated 
from the surrounding tumor stroma by characteristic, of-
ten mucin-containing clefts, which are visible in vivo by 
reflectance confocal microscopy and therefore do not 
represent a retraction artifact, as previously believed. The 
superficial variant of BCC more commonly develops on 
the trunk or the limbs, is slightly infiltrated, erythematous 
or partially pigmented and may grow up to several centi-
meters in diameter. The aggregates of basaloid tumor 
cells bud from the interfollicular epidermis and appear to 
be multifocal but, in fact, represent a superficial reticu-
lated network of tumor strands. Tumor growth in super-
ficial BCC remains restricted to the upper dermis with a 
tumor depth less than 0.5 mm. Progression into nodular 
 Fig. 3. Nodular BCC with marked telangiectasias on the right tem-
ple. 
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or morpheiform BCC, however, can take place. A prom-
inent tumor stroma and an inflammatory infiltrate are 
almost invariably present in superficial BCC, although 
the infiltrate is reported to be less pronounced in BCC
of OTR than in the general population  [10] . The mor-
pheiform variant of BCC manifests as a depressed, often 
hypopigmented, scar-like lesion. The histology is charac-
terized by an ill-defined proliferation of small strands of 
basaloid tumor cells embedded in a dense, sclerotic stro-
ma. Perineural growth is not uncommon. Basosquamous 
(cell) carcinoma is considered a variant of BCC with focal 
squamous differentiation. In OTR, it is a rare tumor with 
an incidence of 0.3% and develops with a long delay of up 
to 13 years after the organ transplant  [24] .
 Surgical excision is the first-line therapy for nodular 
and morpheiform BCC. Micrographically controlled ex-
cision or Mohs surgery is indicated for lesions in specific 
body regions (the nose and eye) to limit surgical defects, 
for recurrent BCC and for tumors with perineural growth. 
For superficial BCC, treatment with photodynamic ther-
apy, cryosurgery or laser surgery, imiquimod and topical 
5-fluorouracil are alternatives to surgical excision. The 
prognosis of BCC does not seem to be worse in OTR com-
pared to in the general population  [22, 25] . Recurrence 
after surgical excision has been observed in 10% of RTR 
 [22] . Metastasizing BCC is exceedingly rare. Therefore, 
BCCs in RTR do not require treatment different from that 
for other patient groups. Pathogenetically, genetic altera-
tions in the sonic hedgehog pathway involving patched 
homologue 1 (PTCH1), a tumor suppressor gene, and a 
G-protein-coupled receptor (SMOH) play an important 
role  [23] . Thus, inhibition of the hedgehog pathways rep-
resents a promising therapeutic approach and has been 
employed especially for advanced BCC.
 Adnexal Skin Neoplasms 
 Adnexal skin neoplasms comprise benign or malig-
nant epithelial tumors with differentiation towards hair 
follicle epithelium (trichogenic), eccrine or apocrine 
sweat glands or sebaceous glands. OTR are at increased 
risk for cutaneous adnexal neoplasms which affect 3% of 
OTR  [4] . Most OTR with adnexal skin neoplasms (71%) 
also suffer from other nonmelanoma skin cancers. Be-
nign tumors include pilomatricoma, tumor of the follicu-
lar infundibulum, sebaceous adenoma and eccrine poro-
ma. Malignant adnexal tumors, particularly sebaceous 
carcinoma, seem to be more common in OTR than in the 
general population. Fourteen percent of RTR had multi-
ple adnexal tumors with the head and neck being the pre-
dilection site (74%) [4]. 
 Merkel Cell Carcinoma 
 MCC (a synonym for primary cutaneous neuroendo-
crine carcinoma) is a rare but highly aggressive neoplasm 
with a poor prognosis. The relative risk of OTR develop-
ing MCC is 0.13 per 100 person-years and is 5- to 10-fold 
more than in the general population  [26] . Risk factors are 
exposure to UV light, age, chronic lymphocytic leukemia 
and immunosuppression. MCC shows a male preponder-
ance and affects OTR mostly in their fifth decade, with a 
latency of 7.6 years after the organ transplant (range 
5–286 months)  [27] . Predilection sites are UV-light-ex-
posed skin regions, particularly the head and neck. Usu-
ally, MCC presents as a solitary, rapidly growing, red-to-
bluish dome-shaped nodule, which may ulcerate. In one 
third of the patients, MCC is clinically misinterpreted
as cysts. Histologically, nodular or diffuse infiltrates of 
small- to medium-sized basaloid-appearing or blast-like 
cells with hyperchromatic nuclei, focal necrosis and mi-
toses are found. The trabecular growth pattern with rib-
bons of tumor cells is rarer. Occasionally, focal squamous 
differentiation can be observed. Small-cell type and vas-
cular invasion are considered as histological markers of 
poor prognosis. At the periphery of the tumor, dissection 
of collagen bundles by strands of tumor cells or scattered 
single tumor cells with small hyperchromatic nuclei may 
be misinterpreted as peritumoral lymphocytic infiltrate. 
Tumor cells in MCC may display pagetoid spread into the 
overlying epidermis which has to be distinguished by im-
munohistochemistry from malignant melanoma, Paget’s 
disease, SCC in situ with pagetoid growth and sebaceous 
carcinoma  [28] . Occasionally, MCC contains a dense in-
tra- and peritumoral lymphocytic infiltrate which may 
mimic lymphoma or pseudolymphoma and obscure tu-
mor cells  [29] . Collisions of MCC and SCC in situ, inva-
sive SCC or BCC have been reported  [30] . Tumor cells in 
MCC express pancytokeratin (in 100% of cases) and cy-
tokeratin 20 (CK20; in 65–93%) with a characteristic peri-
nuclear dot-like pattern ( fig. 4 ), CAM5.2 (in 100%) and 
EMA (in 100%). The tumor cells express the neuroendo-
crine markers synaptophysin (67–75%) and chromo-
granin (75%) as well as CD56 (N-CAM). A recent study 
showed that p63 expression represents a strong risk fac-
tor for shortened survival, but this finding has yet to be 
confirmed by studies on larger cohorts  [31] .
 The clonal integration of Merkel cell polyomavi-
rus (MCPyV) DNA into tumor cell DNA indicates that 
this polyomavirus contributes to tumor development. 
MCPyV is present in the majority (60–90%) of MCC cas-
es. The presence of MCPyV DNA, however, is not re-
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stricted to MCC; viral DNA has also been found in other 
benign and malignant neoplasms such as nonmelanoma 
skin cancers, seborrheic keratoses and common warts 
 [32] , and may be carried to these lesions via blood-borne 
inflammatory CD14+ CD16– monocytes serving as a res-
ervoir for MCPyV  [33] . In comparison, detection of the 
large T antigen of MCPyV by immunohistochemistry is 
a useful adjunctive marker for the diagnosis of MCC  [34] . 
MCC metastasizes in 68% of the patients  [35] . Sentinel 
lymph node biopsy has therefore been recommended for 
MCC. Prognosis is generally poor with a 5-year-survival 
rate of less than 50%. Treatment includes local wide ex-
cision, radiotherapy and multiagent chemotherapy for 
metastatic disease.
 Kaposi’s Sarcoma 
 KS accounts for 5.7% of all cancers in OTR. Its inci-
dence is 400- to 500-fold more than in the nontransplant 
population  [36] . KS often occurs sooner after organ trans-
plantation than nonmelanoma skin cancers, with an aver-
age delay after surgery that ranges from 2 months to 18 
years (mean 13 months)  [36, 37] . The male to female ratio 
is 1: 2–3 in immunocompromised patients and hereby 
differs from the ratio in classic KS (17: 1). Three clinical 
and histological stages (patch – plaque – tumor) can be 
distinguished.
 The early skin lesions (patch stage) are characterized 
by a proliferation of dilated, irregularly shaped and thin-
walled vessels lined by a single layer of flattened endothe-
lial cells lacking significant atypia ( fig. 5 ). These vessels 
dissociate dermal collagen bundles and surround preex-
isting blood vessels and skin appendages, a phenomenon 
termed promontory sign. Extravasated erythrocytes and 
hemosiderin deposits are present. The intra- and peri-
tumoral inflammatory infiltrate consists of plasma cell, 
lymphocytes and macrophages. Progressive lymphangio-
ma and targetoid hemosiderotic hemangioma have to be 
differentiated from early KS. In addition, the findings in 
early or patch-stage KS are subtle and may be misdiag-
nosed as inflammatory dermatosis. In the plaque and 
nodular stages, a proliferation of spindle-shaped cells 
predominates with slit-like vessels sometimes filled by 
erythrocytes. Cytological atypia of tumor cells is relative-
ly subtle, in contrast to angiosarcoma. Clinical and histo-
logical variants of KS include the micronodular form, 
presenting with tiny red papules clinically resembling 
capillary hemangioma, and hyperkeratotic (verrucous), 
keloidal, molluscoid, pyogenic granuloma-like and intra-
vascular KS  [38, 39] . The tumor cells express endothelial 
markers (CD31, CD34 and von Willebrand factor/factor 
VIII), podoplanin and PROX-1.  Human herpesvirus 8 
(HHV-8) is the etiologic agent of KS. Immunohisto-
chemical detection of HHV-8 is a crucial diagnostic tool 
with a high sensitivity and specificity  [40] . HHV-8 in-
duces a reprogramming of CD34+ blood endothelial cells 
to express a lymphatic phenotype [podoplanin (PROX-
1)]. Viral proteins of HHV-8 such as vIL-6 or v-cyclin 
result in deregulation of the cell cycle, inhibition of apop-
tosis of tumor cells and suppression of antitumoral host 
immune response. The virus is usually acquired months 
to years before the occurrence of KS. HHV-8 can be trans-
mitted by horizontal and vertical transmission via sexual 
contact, blood or body fluids. In OTR, KS usually devel-
ops following HHV-8 reactivation, although transmis-
sion from the graft is not uncommon. In contrast to the 
classic form of KS, which runs a slowly progressive and 
indolent course, the 5-year survival rate of KS in OTR is 
69%  [41] . Mucocutaneous lesions of KS are found in 
more than 75% of OTR with 25–50% of the patients de-
veloping visceral lesions during the course of the disease 
 [36] . Treatment of KS in OTR comprises a reduction of 
immunosuppressive drugs, which leads to complete re-
 Fig. 4. Characteristic perinuclear dot-like 
pattern of cytokeratin 20 (red; immunohis-
tochemistry). Original magnification ×200. 
 Fig. 5. KS (patch stage) with irregularly 
shaped and thin-walled vessels dissecting 
dermal collagen bundle. HE. Original mag-
nification ×200. 
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mission in 25–30% of patients but carries the risk for re-
jection of the transplanted organ, switching the immuno-
suppressive medication to an mTOR inhibitor, surgical 
excision, radiotherapy, intralesional bleomycin injection, 
liposomal anthracyclines and interferon alpha. Clinical 
tumor regression after topical treatment with imiquimod 
does not necessarily indicate complete tumor regression 
as, histologically, tumor persistence has been identified 
 [42] . 
 Cutaneous Melanoma 
 The risk for cutaneous melanoma (CM) is only slight-
ly increased, but CM shows a significant mortality  [1, 43, 
44] . It accounts for approximately 6% of skin cancers in 
OTR and mostly affects young patients (mean age 36 
years) with a male preponderance. It develops after a me-
dian posttransplant delay of 4–5 years  [1, 43, 45, 46] . Risk 
factors for CM in OTR include intermittent exposure to 
UV light (and sunburns), inability to tan, multiple and 
dysplastic nevi as well as a family history of CM. The clin-
ical presentation does not differ from that in immuno-
competent individuals  [46] . Histologically, CM is char-
acterized by asymmetrical architecture, cellular atypia
of melanocytes arranged as single units or in confluent 
nests, intraepidermal pagetoid spread of atypical melano-
cytes and a lack of maturation of the intradermal compo-
nent of the neoplasm. Early forms of acral lentiginous and 
mucosal CM show only subtle findings with a few atypical 
melanocytes in the junctional area. Lentigo melanoma in 
situ (so-called lentigo maligna) is prone to being misin-
terpreted as dysplastic nevus, particularly in incisional
biopsies. Therefore, melanocytic lesions with dysplastic 
features occurring in UV-light-exposed skin should be 
completely excised. 
 The desmoplastic variant of CM (DM) typically aris-
es from lentigo maligna, manifests with a diffuse prolif-
eration of spindle-cell tumor cells and may completely 
lack pigmentation. Staining for S-100 protein and p75 
are the most sensitive markers for DM, whereas other 
melanocytic markers are often absent. Prognostic crite-
ria in CM are tumor thickness (TD; Breslow index), mi-
totic index (in MM with a TD <1 mm), and ulceration. 
In a series of OTR reported in 1996, MM showed a TD 
>0.76 mm or greater than Clark’s level III in 69% of
patients  [45] . In a recent study, however, the TD was
<1 mm in the majority of cases  [44] , which may be as a 
result of closer screening of OTR for skin cancers. CM 
with Breslow thickness <2 mm in OTR has a similar 
prognosis to tumors in the general population, whereas 
MM with Breslow thickness >2 mm exhibits a worse 
prognosis than CM in immunocompetent individuals 
 [47] . Sentinel lymph node biopsy is recommended for 
cases with a TD of between 1 and 4 mm and/or stage 
pT1b (AJCC classification, 2010) with a mitotic index of 
>1 mitosis per mm 2 . Interestingly, melanocytic tumors 
from OTR have been found to have a lower frequency
of BRAFV600E mutations than similar lesions from
immunocompetent individuals (45.4 vs. 63.5%, p < 0.05) 
 [48] . A reduction of immunosuppressive treatment is 
recommended for OTR with CM  [19] . In patients with 
CM prior to organ transplantation, there seems not to 
be a higher risk for recurrence or metastasis.
 Cutaneous Lymphomas 
 PTLD represent lymphoid proliferations developing 
as a consequence of immunosuppression in a recipient of 
a solid organ, bone marrow or stem cell allograft. PTLD 
affects 1–5% of solid OTR, but primary cutaneous lym-
phomas in OTR appear to be rare and so far only a few 
cases have been reported. They develop 5–8 years after 
organ transplantation  [1, 49] . According to the WHO 
classification (2008; 4th edition), PTLD is classified as 
early lesions, polymorphic, monomorphic PTLD and 
classic Hodgkin lymphoma-type PTLD [50]. In contrast 
to nodal and other extranodal lymphomas in OTR, 70% 
of primary cutaneous lymphomas in OTR are of T cell 
origin, whereas only 30% are cutaneous B cell lymphomas 
[Seckin, submitted]. Mycosis fungoides and cutaneous 
CD30+ lymphoproliferative disorders (CD30+ LPD) ap-
pear to be the most common forms of primary cutaneous 
lymphomas of T cell origin. MF presents with erythema-
tous and slightly scaling patches and plaques mostly on 
the trunk. Histologically, the disease is characterized by 
an epidermotropic infiltrate of atypical small to medium-
sized lymphocytes. Similar to other patients with MF, the 
disease in OTR appears to progress slowly. Cutaneous 
CD30+ LPD manifest with nodular, often ulcerated le-
sions. In contrast to CD30+ LPD in the general popula-
tion, spontaneous regression of tumoral lesions is not ob-
served in OTR. Histologically, dense infiltrates of large 
pleomorphic and anaplastic lymphoid cells are seen  [51] . 
By definition, more than 75% of tumor cells express CD30 
in addition to T cell markers (CD2, CD4 and CD8). 
CD30+ LPD run an aggressive course in OTR, which is in 
contrast to the excellent prognosis of cutaneous CD30+ 
LPD in the general population. Staging examinations are 
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essential to distinguish the primary cutaneous from the 
systemic form of CD30+ LPD. The epidemiology and 
composition of cutaneous B cell lymphomas in OTR dif-
fer significantly from those in immunocompetent pa-
tients. In OTR, B cell lymphomas are often monomorphic 
and of large-cell morphology (centroblastic, immuno-
blastic and plasmablastic)  [49] . The vast majority are as-
sociated with Epstein-Barr virus as shown by the presence 
of Epstein-Barr virus RNA transcripts (EBER) by in situ 
hybridization. 
 Conclusions 
 OTR are at a significantly increased risk for developing 
a wide variety of skin cancers. As atypical clinical mani-
festations are not infrequent and the accuracy of clinical 
diagnosis is limited, histopathology plays a crucial role in 
the diagnostic workup of skin cancer in OTR and may 
also provide important prognostic data.
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